We’re not generally in the awards business here at STAT (with a few exceptions), but as we reflected back on this year, we felt one company stood out for rebounding from tough times. So we hereby anoint Juno Therapeutics (JUNO) as the comeback company of the year.

Few have forgotten Juno’s worst moment: the deaths of five patients with advanced acute lymphoblastic leukemia who were being treated with the company’s experimental CAR-T therapy known as JCAR015. The Food and Drug Administration quickly put the JCAR015 program on clinical hold; later, the study was scuttled entirely.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy